Global Cancer Gene Therapy Market to Grow at a CAGR of 20.6% by 2021: Key Vendors are Adaptimmune, Bluebird bio, Celgene, Shanghai Sunway Biotech, Shenzhen SiBiono GeneTech & SynerGene Therapeutics – Research and Markets

DUBLIN--(BUSINESS WIRE)-- The "Global Cancer Gene Therapy Market 2017-2021" report has been added to Research and Markets' offering.

The global cancer gene therapy market to grow at a CAGR of 20.63% during the period 2017-2021.

The report, Global Cancer Gene Therapy Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

According to the report, one driver in the market is rising geriatric population. The global geriatric population is continues to grow at a faster pace due to several factors such as rapidly falling fertility rates and growing life expectancy due to better medical facilities. The US Census Bureau reported that the total population aging 65 years and above was estimated at 617 million in 2015 and is expected to rise to 1,566 million by 2050.

Asia has the largest and fastest growing aging population due to several factors such as the huge population of the region, government policies such as one child policy of China has reduced the addition of young population, and higher investment in the healthcare sector has led to better medical facilities and longer life expectancy.

Key vendors

• Adaptimmune
• Bluebird bio
• Celgene
• Shanghai Sunway Biotech
• Shenzhen SiBiono GeneTech
• SynerGene Therapeutics

Other prominent vendors

• Altor BioScience
• Amgen
• argenx
• BioCancell
• GlaxoSmithKline
• Merck
• OncoGenex Pharmaceuticals
• Transgene

Key Topics Covered:

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03: Research Methodology

Part 04: Market Landscape

Part 05: Pipeline Analysis

Part 06: Market Segmentation By Therapy

Part 07: Geographical Segmentation

Part 08: Decision Framework

Part 09: Drivers And Challenges

Part 10: Market Trends

Part 11: Vendor Landscape

Part 12: Key Vendor Analysis

Part 13: Appendix

For more information about this report visit https://www.researchandmarkets.com/research/hrzr8h/global_cancer

View source version on businesswire.com: http://www.businesswire.com/news/home/20170815005475/en/

Research and Markets

Laura Wood, Senior Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

Related Topics: Genomics, Oncology Drugs

Source: Research and Markets